Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bulaquine
- Development stage
- Unknown
- Lead developer
- CSIR-Central Drug Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bulaquine is a synthetic small molecule antimalarial drug belonging to the 8-aminoquinoline class, developed as a derivative of primaquine by the Central Drug Research Institute (CDRI) in India. It functions as both a gametocytocidal agent, targeting the gametocytes of *Plasmodium falciparum* to interrupt transmission, and an antirelapse agent, targeting the hypnozoites of *Plasmodium vivax*. It is typically prescribed for the radical cure of malaria in combination with chloroquine. The drug was developed in collaboration with Nicholas Piramal India Ltd and the Council of Scientific & Industrial Research (CSIR) and is marketed in India under the brand name Aablaquin. Like other 8-aminoquinolines, caution is advised in patients with G6PD deficiency due to the risk of hemolysis.
- Brand names
- Aablaquin
- Other names
- AablaquineElubaquine
Beyond the preview
Go deeper on bulaquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bulaquine.